Publications by authors named "S Feleus"
Background And Objectives: The total functioning capacity (TFC) assessment has been integral to Huntington's disease (HD) research and clinical trials, measuring disease stage and progression. This study investigates the natural progression of function in HD, focusing on changes in TFC scores related to age and CAG-repeat length, and evaluates TFC's strengths and weaknesses in longitudinal studies.
Methods: Using Enroll-HD platform's clinical dataset version 5, including Registry-3, we analysed data from 21,079 participants, with 16,083 having an expanded CAG repeat.
Background: Proper medication reconciliation (= comparing the accuracy of patient-reported medication use with pharmacy records) could prevent potentially dangerous situations such as drug-drug interactions and hospitalization. This is particularly important when patients rely on multiple medications, such as in neurodegenerative disorders like Huntington's Disease (HD). Currently, it is unknown how often medication discrepancies occur in HD patients and which factors contribute to the discrepancies.
View Article and Find Full Text PDFArticle Synopsis
- Huntington's Disease (HD) requires careful medication management, with limited information on real-world medication use across different stages of the disease.
- Data from the ENROLL-HD study shows that medication use increases significantly as HD progresses, with 84.6% of patients using medications, particularly antipsychotics, SSRIs, and painkillers.
- Differences in medication use were noted based on sex and regional factors, and unique patterns emerged in childhood-onset HD, highlighting the need for personalized treatment approaches in managing the disease.
Background: Juvenile-onset Huntington's disease (JHD) represents 1-5% of Huntington's disease (HD) patients, with onset before the age of 21. Pediatric HD (PHD) relates to a proportion of JHD patients that is still under 18 years of age. So far, both populations have been excluded from interventional trials.
View Article and Find Full Text PDFArticle Synopsis
- * The primary goal of this study is to analyze how genetic variations in the CYP2C19 and CYP2D6 genes in HD gene expansion carriers impact negative medication effects related to HD treatments.
- * The research will involve collecting data from HD patients over a year using various methods, and will compare the effects of medications based on patients' genetic profiles to improve treatment outcomes and reduce side effects. *